SEC Form 4 · accession 0000899243-18-026752
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A. Fair
Director
Period of report
Oct 11, 2018
Accepted (ET)
Oct 15, 2018 · 9:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $27.92 | Oct 11, 2018 | A | 25,848 | A | — | Oct 11, 2028 | Common Stock | 25,848 | 25,848 | D |
Explanation of responses
- F1One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant.